KBI Biopharma Acquires Bioanalytical Firm
KBI Biopharma (KBI), a biopharmaceutical contract development and manufacturing organization, has agreed to acquire the assets of San Diego-based Alliance Protein Laboratories, an analytical services company specializing in biophysical characterization of biopharmaceuticals.
Alliance characterizes therapeutic proteins, peptides, nucleic acids, and vaccines. The acquisition will expand KBI’s capabilities to include analytical ultracentrifugation.
All of Alliance’s staff, including co-founders Tsutomu Arakawa, PhD, and John Philo, PhD, will join KBI through the acquisition with both continuing to oversee operations in the San Diego-based laboratory.
KBI is investing $30 million to expand its biopharmaceutical manufacturing capacity and capabilities at its facilities in Durham, North Carolina and Boulder, Colorado. In February, it added to its cell therapy development and manufacturing operations in The Woodlands, Texas, and recently announced that its parent company, JSR Life Sciences, would acquire Geneva-based Selexis SA, a provider of cell-line technologies, to integrate it with KBI.
Source: KBI Biopharma